wherein one of R^5 is $(CH_2)_yZ$, $(CH_2CH_2O)_xCH_2CH_2Z$ or $(CH_2)_yNH\text{-}CO\text{-}(CH_2CH_2O)_x\ CH_2CH_2Z$, wherein x is 1-100, y = 1-6, and the other R^5 is H or unsubstituted alkyl.

18. The compound of Claim 17 wherein R^1 is CN or CH_3SO_2; R^2 is H; one R^5 is $(CH_2)_yZ$ wherein y is 5; and the other R^5 is H.

19. The compound of any of Claims 15-18 wherein E is a stabilized exendin comprising an amino acid substitution at the position corresponding to N28 in the native exendin sequence, wherein the native exendin consists of SEQ ID NO:1 or SEQ ID NO:7.

20. The compound of Claim 19 wherein E is N29D, N28A, N28K or N28Q substituted SEQ ID NO:1 or SEQ ID NO:7.

21. The compound of Claim 20 wherein E is SEQ ID NO:2.

22. Use of the conjugate of any of claims 1-5 in the manufacture of a medicament to be administered to a subject for the treatment of a condition benefited by a GLP-1 agonist, wherein the medicament is to be administered at one dosage per one to three months.

23. A peptide of the formula:

HGEGTFTSDL SKQMEEEAVR LFIEWLKQGG PSSGAPPPS-NH_2

(SEQ ID NO:2) ([N28Q]exenatide) or a pharmaceutically acceptable salt thereof.

24. A pharmaceutical composition comprising as active ingredient the peptide or salt of claim 23.

25. Use of the peptide or salt of claim 23 or the pharmaceutical composition of claim 24 in the manufacture of a medicament to be administered to a subject for the treatment of a condition benefited by a GLP-1 agonist.